Alpine Immune Sciences reveals new study results for Lupus treatment at 2023 Rheumatology Convergence

Alpine Immune Sciences, Inc., a frontrunner in the clinical-stage immunotherapy field, specializing in pioneering solutions for autoimmune and inflammatory ailments, has proclaimed the introduction of fresh translational data related to acazicolcept (ALPN-101) utilized for systemic lupus erythematosus. The information was delivered during the American College of Rheumatology Convergence in 2023, from November 10th to 15th.

👇Please click on the image below to directly access the latest data (R&D Status | Core Patent | Clinical Trial | Approval status in Global countries) of this drug.

In comparison to healthy adults, acazicolcept-targeted genes (ICOS, CD80, CD86) display increased expression in T and B cells of SLE patients. Acazicolcept is able to suppress the expression of genes tied to T cell activation and/or involved in SLE pathogenesis more effectively than CD28 or ICOS pathway inhibitors.

Stanford Peng, M.D., Ph.D., President and Head of Research and Development at Alpine, commented that such findings highlight the crucial role of several key pathways in SLE pathogenesis and offer further support for the prospect of acazicolcept, a pioneer molecule, in SLE treatment. Adding further, Peng stressed that due to the close association of CD28 and ICOS as mediators of T cell costimulation, the inhibition of both might be necessary to achieve optimal results in various autoimmune diseases. Peng consistently backs the clinical assessment of acazicolcept for SLE treatment, as ongoing in their Synergy phase 2 trial.

Being a first-of-its-kind, dual inhibitor of the CD28 or ICOS T-cell costimulatory pathways, acazicolcept (ALPN-101) is under development for systemic lupus erythematosus treatment. By blocking two major costimulatory pathways at the same time, acazicolcept could potentially enhance outcomes for patients battling severe autoimmune/inflammatory conditions. In preclinical studies, efficacy has been shown in SLE, Sjögren's syndrome, arthritis, inflammatory bowel disease, multiple sclerosis, type 1 diabetes, uveitis, and graft versus host disease models.

👇Please click on the picture link below for free registration or login directly if you have freemium accounts, you can browse the latest research progress on drugs, indications, organizations, clinical trials, clinical results, and drug patents related to this target.

According to the data provided by the Synapse Database, As of November 21, 2023, there are 1 investigational drugs for the CD28 and ICOS target, including 12 indications, 1 R&D institutions involved, with related clinical trials reaching 5, and as many as 12525 patents.

Acazicolcept has a broad therapeutic potential, covering various diseases related to the immune system, inflammation, and other medical conditions. Its active indications include systemic lupus erythematosus, graft vs host disease, and multiple sclerosis, among others. Acazicolcept has been designated as an orphan drug, indicating its focus on treating rare diseases.